Monitor for top-line data from the FOCUS-2 trial (timeline undisclosed). No near-term revenue or regulatory catalyst, solriamfetol is already in earlier-stage ADHD trials, so this is an incremental step. The stock likely sees limited reaction to a dosing announcement alone.
Drug in focus
AXSM drug pipeline →solriamfetol
● Neutral Named in this press release- Impact
- Phase
- Approved
- Time to market
- Already approved and marketed (Sunosi, FDA-approved 2019)
- Next catalyst
- None dated
What to watchSolriamfetol is a steady commercial contributor (~$125M FY2025, 32% YoY) with patent protection through 2040, but it is not Axsome's primary growth driver, Auvelity is larger (~$291M in 2024) and just won an Alzheimer's agitation approval. Watch for whether Axsome files an ADHD sNDA in 2H 2026 or 2027, which would create a new regulatory catalyst. Until then, solriamfetol's value is in its reliable cash flow and pipeline-expansion optionality.
How the stock moved after the report
NEUTRAL VIEWSTOCK BELOW ENTRY AT T+60- T+0 · Jul 7 $249.76entry
- T+1 · 4mo ago −1.68%α −1.37% · $245.57
- T+5 · 4mo ago −5.81%α −6.36% · $235.26
- T+20 · 4mo ago −15.50%α −16.84% · $211.04
- T+60 · 7w ago −26.17%α −28.38% · $184.39
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
Axsome announced the first patient dosed in the FOCUS-2 Phase 3 trial of solriamfetol for children with ADHD, a 468-patient placebo-controlled study. This is a pipeline-progression event that extends the solriamfetol ADHD program into a younger pediatric population, but no efficacy data or commercial timelines were provided. The event is positive for the pipeline narrative but lacks financial impact or near-term catalyst.
Key Facts
- First patient dosed in FOCUS-2 Phase 3 trial evaluating solriamfetol for children aged 6 to <12 with ADHD
- Trial is randomized, double-blind, placebo-controlled; ~468 patients randomized 1:1:1 to one of two solriamfetol doses or placebo for 6 weeks
- Primary endpoint: change from baseline to week 6 on ADHD-RS-5 total score
- Previously Axsome initiated FOCUS-3 Phase 3 trial of solriamfetol in adolescents (12 to <18) with ADHD
- No financial terms, cash runway implications, or timeline for data readout disclosed in the release
Financial Impact
No financial figures disclosed; pipeline expansion has no near-term revenue impact
Risk Factors
- Phase 3 trial could fail on primary endpoint (ADHD-RS-5), which would impair solriamfetol's ADHD label expansion potential
- Regulatory pathway in pediatric ADHD is untested for solriamfetol; safety and efficacy data required
- Competition from existing ADHD treatments (stimulants, non-stimulants) may limit commercial opportunity even if approved
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 press release from GlobeNewswire.
| Document | Accession Number |
|---|---|
| PRESS-RELEASE Data (Synthetic) | press-3323028 |
Track record
26 reports on AXSM
6 of 8 bullish or bearish reports moved the stock their way by T+5. Best: +14.74% at T+60 after the Apr 30, 2026 report. 7 of 8 went positive at some point.
Filters
- Nov 2, 202614d ago 8-K Bullish 6/10 No price data
- Nov 2, 202614d ago Press Release Bullish 6/10 Entry $136.01 to $133.96 Now $137.01 +0.74% ▼ −1.51% −1.59% vs SPY
- Oct 20, 202627d ago Institutional Cluster Bearish 4/10 Entry $156.31 to $142.20 Now $137.01 +12.35% ▲ +9.03% +8.58% vs SPY
- Aug 11, 202613w ago Institutional Cluster Mixed 5/10 Entry $214.66 to $218.20 Now $137.01 −36.17% ▲ +1.65% +2.09% vs SPY
- Aug 10, 202614w ago 8-K Neutral 6/10 No price data
- Aug 10, 202614w ago Press Release Mixed 6/10 Entry $220.89 to $216.27 Now $137.01 −37.97% ▼ −2.09% −2.04% vs SPY
- Jul 15, 202617w ago Press Release Bullish 6/10 Entry $237.53 to $239.62 Now $137.01 −42.32% ▲ +0.88% +1.86% vs SPY
- Jul 9, 202618w ago Court Ruling Bullish 5/10 Entry $248.95 to $237.04 Now $137.01 −44.96% ▼ −4.78% −4.65% vs SPY
- Jul 7, 202618w ago Press Release Neutral 4/10 Viewing Entry $249.76 to $235.26 Now $137.01 −45.14% ▼ −5.81% −6.36% vs SPY
- Jul 1, 202619w ago 144 Neutral 4/10 Entry $244.31 to $248.95 Now $137.01 −43.92% ▲ +1.90% +0.97% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers